Lipid Genomics Team

Founder:

Dr. Annabelle Rodriguez is an internationally recognized expert in cholesterol metabolism, and the genetics of the HDL receptor SCARB1. Dr. Rodriguez's research team published the first report connecting the immune checkpoint inhibitor LAG3 to coronary artery disease. She has published numerous peer-reviewed academic publications, received highly competitive NIH and foundation research awards and is an editor of the newly published book, Translational Cardiometabolic Genomic Medicine. Dr. Rodriguez is an inventor on seven patents that have been published and/or granted, which support the intellectual property owned by Lipid Genomics.

Dr. Rodriguez graduated from New Jersey Medical School, completed a residency in internal medicine at Thomas Jefferson University Hospital, a postdoctoral fellowship in physiology and biochemistry at Medical College of Pennsylvania, and an endocrinology fellowship at Johns Hopkins University School of Medicine.

Business Manager:

Mr. Ray Oquendo is responsible for identifying and developing new and existing sources of capital, building long-term relationships with new and existing customers and promoting the company’s products and services. Prior to joining Lipid Genomics, Mr. Oquendo worked for the IBM Corporation, in the Global Sales Solutions for cross industry applications. He received numerous awards for his sales performance and leadership skills. Ray served in several management and technical leadership positions within IBM.